Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
ORGANIZATION
PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
Major pharma trade organizations issued statements on December 25 following the Japanese government’s decision to push ahead with an “off-year” drug price revision in FY2025, with US and European groups harshly criticizing it as a reversal of pro-innovation policies. The…
To read the full story
Related Article
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
ORGANIZATION
- PhRMA Japan Chief Laments CEA Expansion, Calls for Sweeping Reform
November 20, 2026
- Ex-MHLW Bureau Chief Jo Joins Patient Support Foundation
November 20, 2026
- JPMA, EFPIA Follow PhRMA in Decrying CEA Price Cut Expansion
November 19, 2026
- PhRMA Slams CEA Expansion, Warns It Undermines Japan Growth Strategy
November 17, 2026
- UCB Japan President Kikuchi to Take Helm of EFPIA Japan
November 13, 2026





